Pharma Companies Need Better Incentives, Innovation To Invest In Neglected Diseases

EurActiv.com: Pharma firms pressed to tackle neglected diseases in developing world
“Poverty-related and neglected diseases (PRNDs) disproportionately affect the world’s poorest populations. Better incentives are needed for pharmaceutical companies to develop drugs, health campaigners say. Europe plays a critical role in developing new PRND products that are saving millions of lives and millions of euros in the world’s poorest countries…” (Jacobsen, 3/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.